Rocket Doctor AI Inc. (CSE: AIDR) announced on October 15, 2026 that it completed 53,348 patient visits across Canada and the United States in the third quarter ended September 30, 2026. U.S. visits surged 56% quarter-over-quarter while Canadian visits rose 24% year-over-year. The company expects to report record quarterly revenue for Q3 2026, citing improving cash collections relative to clinical activity. Investors may be watching how quickly revenue recognition catches up to the strong volume growth.

Key Points

  • Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) disclosed Q3 2026 operational results
  • Total completed patient visits reached 53,348, comprising 6,101 U.S. visits and 47,247 Canadian visits
  • U.S. visits grew 56% from Q2 2026; Canadian visits grew 24% from Q3 2025; U.S. clinical hours rose 33% to 2,634 hours quarter-over-quarter
  • Investors should watch whether Q3 revenue results confirm the company's record-quarter expectation once formally reported

Q3 2026 Patient Visit Volumes Across U.S. and Canadian Markets

Rocket Doctor AI completed 6,101 U.S. patient visits in Q3 2026, up 56% from 3,911 visits recorded in Q2 2026. Canadian visits reached 47,247, representing a 24% increase compared with 37,960 visits in the same quarter a year earlier. U.S. clinical hours also expanded, rising 33% to 2,634 hours from 1,987.5 hours in Q2 2026. The release states that final U.S. visit volumes exceeded the preliminary indicators communicated in the company's September 14, 2026 operational update, suggesting stronger-than-anticipated quarter-end momentum.

Multi-Payer Strategy Driving U.S. Visit Growth

The company attributed U.S. volume growth to continued execution of its multi-payer strategy, which the release states encompasses a network of over 20 in-network payer agreements spanning commercial, Medicare Advantage, and Medicaid verticals across key state markets. The disclosure notes that Rocket Doctor AI distinguishes between in-network and out-of-network patients when determining reimbursement eligibility. For out-of-network visits, the company states it permits platform access to drive adoption, while claims are submitted where possible and any recoveries are recognised only upon cash receipt.

Revenue Timing Lag and Record Q3 Revenue Expectation

The announcement highlights a known timing lag between patient visit completion and revenue recognition under the company's cash-basis accounting policy for certain U.S. revenues. Rocket Doctor AI noted that significant U.S. visit growth in Q2 2026 was not immediately reflected in reported revenue because of delays in claims processing and cash collections. With U.S. visits rising a further 56% in Q3, the company expects collections to begin catching up to clinical activity, supporting its expectation of record quarterly revenue for Q3 2026. The exact revenue figure was not disclosed in the announcement.

Platform Scale and Operational Foundation

Rocket Doctor AI describes itself as a physician-built, AI-powered healthcare technology platform that has facilitated more than 800,000 cumulative patient visits and empowered over 350 physicians. The company states its technology enables doctors to independently launch and manage virtual or hybrid practices, with a focus on underserved, rural, and remote Canadian communities, as well as Medicaid and Medicare patients in the United States. Surpassing 50,000 total visits in a single quarter represents what the company characterises as a significant operational milestone.